Table of Contents Table of Contents
Previous Page  1714-1715 / 3581 Next Page
Information
Show Menu
Previous Page 1714-1715 / 3581 Next Page
Page Background

ESTRO IG and Adaptive

Course Parikh 25.10.2016

No Grade 3 toxicity at

median 11.8 mo f/u

Expected 20-30% using

aggressive dose

regimen

No change in patient-

reported EORTC-qlq 30

QOL scores (

P =

0.29)

at 0, 6, and 12wks.

Phase I Results—Clinical Outcomes

0

10

20

30

40

50

60

70

80

0

6

12

Quality of Life Score

Time Since Completion

of Therapy (weeks)

Mean EORTC-30 QOL Score

Henke et al, ASTRO 2016